Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus no anticoagulation after thoracoscopic lung cancer surgery
ChiCTR2300074296Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Incidence of venous thromboembolism. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2300074296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074296.